

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS
NEWS	18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	19	JAN 25	Annual Reload of MEDLINE database
NEWS	20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:43:45 ON 17 FEB 2010

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:43:56 ON 17 FEB 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2010 HIGHEST RN 1206588-85-3

DICTIONARY FILE UPDATES: 15 FEB 2010 HIGHEST RN 1206588-85-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10593911.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 16
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-8 8-9 8-11 9-10 11-12 12-13 12-14 14-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
5-7 7-8 8-9 8-11 9-10 12-13 15-16
exact bonds :
11-12 12-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:O,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1 STR

```



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:44:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 550 TO ITERATE

100.0% PROCESSED 550 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 9593 TO 12407

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 11:44:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10566 TO ITERATE

100.0% PROCESSED 10566 ITERATIONS

62 ANSWERS

SEARCH TIME: 00.00.02


L3 62 SEA SSS FUL L1

=> d scan

L3 62 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN Acetamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-

MF C17 H27 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

191.54

191.76

FILE 'CAPLUS' ENTERED AT 11:44:36 ON 17 FEB 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Feb 2010 VOL 152 ISS 8

FILE LAST UPDATED: 16 Feb 2010 (20100216/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:43:45 ON 17 FEB 2010)

FILE 'REGISTRY' ENTERED AT 11:43:56 ON 17 FEB 2010

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 62 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:44:36 ON 17 FEB 2010

=> s 13

L4 3 L3

=> d 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:85132 CAPLUS

DOCUMENT NUMBER: 148:345763

TITLE: Non-charged thiamine analogs as inhibitors of enzyme transketolase

AUTHOR(S): Thomas, Allen A.; De Meese, J.; Le Huerou, Y.; Boyd, Steven A.; Romoff, Todd T.; Gonzales, Steven S.; Gunawardana, Indrani; Kaplan, Tomas; Sullivan, Francis; Condroski, Kevin; Lyssikatos, Joseph P.; Aicher, Thomas D.; Ballard, Josh; Bernat, Bryan; DeWolf, Walter; Han, May; Lemieux, Christine; Smith, Darin; Weiler, Solly; Wright, S. Kirk; Vigers, Guy; Brandhuber, Barb

CORPORATE SOURCE: Array BioPharma Inc., Boulder, CO, 80301, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(2), 509-512

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:345763

AB Inhibition of the thiamine-utilizing enzyme transketolase (TK) has been linked with diminished tumor cell proliferation. Most thiamine antagonists have a permanent pos. charge on the B-ring, and it has been suggested that this charge is required for diphosphorylation by thiamine pyrophosphokinase (TPPK) and binding to TK. We sought to make neutral thiazolium replacements that would be substrates for TPPK, while not necessarily needing thiamine transporters (ThTr1 and ThTr2) for cell penetration. The synthesis, SAR, and structure-based rationale for highly potent non-thiazolium TK antagonists are presented.


IT 866720-78-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(non-charged thiamine analogs preparation as transketolase enzyme inhibitors with better pharmacokinetics)

RN 866720-78-7 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:85131 CAPLUS

DOCUMENT NUMBER: 148:321825
 TITLE: Prodrug thiamine analogs as inhibitors of the enzyme transketolase
 AUTHOR(S): Le Huerou, Yvan; Gunawardana, Indrani; Thomas, Allen A.; Boyd, Steven A.; de Meese, Jason; de Wolf, Walter; Gonzales, Steven S.; Han, May; Hayter, Laura; Kaplan, Tomas; Lemieux, Christine; Lee, Patrice; Pheneger, Jed; Poch, Gregory; Romoff, Todd T.; Sullivan, Francis; Weiler, Solly; Wright, S. Kirk; Lin, Jie
 CORPORATE SOURCE: Array BioPharma Inc., Boulder, CO, 80301, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(2), 505-508
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 148:321825


AB Transketolase, a key enzyme in the pentose phosphate pathway, has been suggested as a target for inhibition in the treatment of cancer. Compound 5a ('N3'-pyridyl thiamin'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of the transketolase cofactor thiamin, is a potent transketolase inhibitor but suffers from poor pharmacokinetics due to high clearance and Cmax linked toxicity. An efficient way of improving the pharmacokinetic profile of 5a is to prepare oxidized prodrugs which are slowly reduced in vivo yielding longer, sustained blood levels of the drug. The synthesis of such prodrugs and their evaluation in rodent models is reported.

IT 866721-14-4

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (prodrug thiamine analogs as inhibitors of transketolase)

RN 866721-14-4 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




IT 866720-78-7


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL
 (Biological study)
 (prodrug thiamine analogs as inhibitors of transketolase)

RN 866720-78-7 CAPLUS


CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




IT 866721-20-2P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prodrug thiamine analogs as inhibitors of transketolase)
 RN 866721-20-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[2-[[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]thio]methyl ester (CA INDEX NAME)



IT 866721-16-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (prodrug thiamine analogs as inhibitors of transketolase)
 RN 866721-16-6 CAPLUS
 CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-chloro-3-pyridinyl)methyl]- (CA INDEX NAME)




IT 866720-79-8P 866720-80-1P 866721-09-7P
 866721-10-0P 866721-17-7P 866721-27-9P
 866721-29-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prodrug thiamine analogs as inhibitors of transketolase)
 RN 866720-79-8 CAPLUS
 CN Acetamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-80-1 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866721-09-7 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-2-[(2-hydroxyethyl)dithio]-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-10-0 CAPLUS

CN Propanoic acid, 3-[[2-[[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]- (CA INDEX NAME)




RN 866721-17-7 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[2-(butylthio)-4-hydroxy-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-27-9 CAPLUS

CN Ethanethioic acid, S-[1-[2-(acetyloxy)ethyl]-2-[[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propen-1-yl] ester (CA INDEX NAME)



RN 866721-29-1 CAPLUS

CN Benzenecarbothioic acid, S-[2-[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-[2-(benzoyloxy)ethyl]-1-propen-1-yl] ester (CA INDEX NAME)




IT 1010816-27-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prodrug thiamine analogs as inhibitors of transketolase)

RN 1010816-27-9 CAPLUS

CN Carbonothioic acid, S-[2-[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl] O-[2-(phenylsulfonyl)ethyl] ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1103748 CAPLUS

DOCUMENT NUMBER: 143:386689

TITLE: Preparation of thioalkeneamides as transketolase inhibitors

INVENTOR(S): Boyd, Steven A.

PATENT ASSIGNEE(S): Array Biopharma Inc., USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095344	A1	20051013	WO 2005-US9966	20050323
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20070293501	A1	20071220	US 2007-593911	20070511
PRIORITY APPLN. INFO.:			US 2004-556218P	P 20040324
			WO 2005-US9966	W 20050323

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:386689; MARPAT 143:386689
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = pyridinyl or pyrazinyl; R1 and R2 independently = H, alkyl or fluoroalkyl; R3 = H, heterocycle, aryl, etc.; R4 = H, alkyl, fluoroalkyl, etc.; R5 = OR7 or NR8R9; R6 = C(O)R, C(S)R, SR, etc.; R7 = C(O)NR2, C(O)OR, (CH2)1-6-C(O)R, etc.; Ra and Rb independently = H, alkyl, fluoroalkyl, etc.; Rc and Rx independently = H, alky or fluoroalkyl; n = 0-4; R = carbocycle, aryl, heteroaryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of transketolase inhibitors. Thus, e.g., II was prepared by coupling of 2-(4-methylthiazol-5-yl)ethanol with 3-chloromethyl-6-methylpyridin-2-ylamine hydrochloride (preparation given) and subsequent ring opening and disulfide bridge formation using potassium ferricyanide. The ability of I to be phosphorylated by thiamine pyrophosphate kinase 1 (TPK1) was evaluated and it was revealed that selected compds. of the invention possessed IC50 values in the range of 10.13 up to 803.23 nM. I as transketolase inhibitors should prove useful in the treatment of neoplasm. Pharmaceutical compns. comprising I are disclosed.

IT 866720-78-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thioalkeneamides as transketolase inhibitors)

RN 866720-78-7 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




IT	866720-68-5P	866720-69-6P	866720-70-9P
	866720-71-0P	866720-72-1P	866720-73-2P
	866720-74-3P	866720-75-4P	866720-76-5P
	866720-77-6P	866720-79-8P	866720-80-1P
	866720-81-2P	866720-82-3P	866720-83-4P
	866720-85-6P	866720-86-7P	866720-87-8P
	866720-88-9P	866720-89-0P	866720-91-4P
	866720-92-5P	866720-93-6P	866720-94-7P
	866720-95-8P	866720-96-9P	866720-97-0P
	866720-98-1P	866720-99-2P	866721-00-8P
	866721-01-9P	866721-06-4P	866721-07-5P
	866721-08-6P	866721-09-7P	866721-10-0P
	866721-11-1P	866721-12-2P	866721-13-3P
	866721-14-4P	866721-15-5P	866721-16-6P
	866721-17-7P	866721-18-8P	866721-19-9P
	866721-20-2P	866721-21-3P	866721-22-4P
	866721-23-5P	866721-24-6P	866721-25-7P
	866721-26-8P	866721-27-9P	866721-28-0P
	866721-29-1P	866721-30-4P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thioalkeneamides as transketolase inhibitors)


RN 866720-68-5 CAPLUS

CN Formamide, N-[2-[[2-[formyl[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-69-6 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-70-9 CAPLUS

CN Formamide, N-[(2-chloro-3-pyridinyl)methyl]-N-[2-[[2-[[2-[(2-chloro-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-71-0 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl[(2-chloro-3-pyridinyl)methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[(2-chloro-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-72-1 CAPLUS

CN Formamide, N-[(6-chloro-3-pyridinyl)methyl]-N-[2-[[2-[[2-[(6-chloro-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-73-2 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl[(6-chloro-3-pyridinyl)methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[(6-chloro-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-74-3 CAPLUS

CN Formamide, N-[2-[[2-[formyl[[2-(methylthio)-3-pyridinyl]methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[[2-(methylthio)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-75-4 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl[[2-(methylthio)-3-pyridinyl]methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[[2-(methylthio)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-76-5 CAPLUS

CN Formamide, N-[2-[[2-[formyl(3-pyridinylmethyl)amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 866720-77-6 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl(3-pyridinylmethyl)amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 866720-79-8 CAPLUS

CN Acetamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-80-1 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-81-2 CAPLUS

CN Acetamide, N-[2-[[2-[acetamido[2-(2-amino-3-pyridinyl)methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[(2-amino-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-82-3 CAPLUS

CN Formamide, N-[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]-N-[2-[[2-[[2-[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-83-4 CAPLUS

CN Acetamide, N-[2-[[2-[acetyl[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]amino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]-4-hydroxy-1-methyl-1-buten-1-yl]-N-[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866720-85-6 CAPLUS

CN Formamide, N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-86-7 CAPLUS

CN Formamide, N-[(2-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-87-8 CAPLUS

CN Formamide, N-[(6-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-88-9 CAPLUS

CN Formamide, N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-N-[[2-(methylthio)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-89-0 CAPLUS

CN Formamide, N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 866720-91-4 CAPLUS

CN Acetamide, N-[(2-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-92-5 CAPLUS


CN Acetamide, N-[(2-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-93-6 CAPLUS
 CN Acetamide, N-[(6-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-94-7 CAPLUS
 CN Acetamide, N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-N-[[2-(methylthio)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 866720-95-8 CAPLUS
 CN Acetamide, N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 866720-96-9 CAPLUS
 CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-97-0 CAPLUS
 CN Formamide, N-[(2-amino-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-98-1 CAPLUS

CN Formamide, N-[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866720-99-2 CAPLUS

CN Acetamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-00-8 CAPLUS

CN Acetamide, N-[(2-amino-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-01-9 CAPLUS

CN Acetamide, N-[(2-amino-4,6-dimethyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-06-4 CAPLUS

CN Phosphoric acid, 4-[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-3-(propyldithio)-3-penten-1-yl diethyl ester (CA INDEX NAME)




RN 866721-07-5 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[(1-methylpropyl)dithio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-08-6 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[(tetrahydro-2-furanyl)methyl]dithio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-09-7 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-2-[(2-hydroxyethyl)dithio]-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-10-0 CAPLUS

CN Propanoic acid, 3-[[2-[[[2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]dithio]- (CA INDEX NAME)




RN 866721-11-1 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[[2-(1-pyrrolidinyl)ethyl]dithio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-12-2 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[[2-(4-morpholinyl)ethyl]dithio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-13-3 CAPLUS

CN Formamide, N-[(2-amino-6-chloro-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-(propyldithio)-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-14-4 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-2,1-ethenediyl]]bis[N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866721-15-5 CAPLUS

CN Formamide, N-[4-(acetyloxy)-2-[[1-[2-(acetyloxy)ethyl]-2-[[2-(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propen-1-yl]dithio]-1-methyl-1-buten-1-yl]-N-[(2-amino-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866721-16-6 CAPLUS

CN Formamide, N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl]]bis[N-[(2-amino-6-chloro-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 866721-17-7 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[2-(butylthio)-4-hydroxy-1-methyl-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-18-8 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[[2-(1-piperidinyl)ethyl]thio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-19-9 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[[2-(phenylsulfonyl)ethyl]thio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-20-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[2-[[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propen-1-yl]thio]methyl ester (CA INDEX NAME)




RN 866721-21-3 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[1-[2-(acetyloxy)ethyl]-2-[[[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propen-1-yl]thio]methyl ester (CA INDEX NAME)




RN 866721-22-4 CAPLUS

CN Formamide, N-[(2-amino-6-methyl-3-pyridinyl)methyl]-N-[4-hydroxy-1-methyl-2-[[[(methylamino)carbonyl]oxy]methyl]thio]-1-buten-1-yl]- (CA INDEX NAME)




RN 866721-23-5 CAPLUS

CN Carbamic acid, dimethyl-, [[2-[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-(2-hydroxyethyl)-1-propenyl]thio]methyl ester (9CI) (CA INDEX NAME)




RN 866721-24-6 CAPLUS


CN Carbamic acid, dimethyl-, [[1-[2-(acetyloxy)ethyl]-2-[(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propenyl]thio]methyl ester (9CI) (CA INDEX NAME)




RN 866721-25-7 CAPLUS
 CN Carbamic acid, dimethyl-, [[2-[[[2-(acetylamino)-6-methyl-3-pyridinyl]methyl]formylamino]-1-[2-(acetyloxy)ethyl]-1-propenyl]thio]methyl ester (9CI) (CA INDEX NAME)




RN 866721-26-8 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[2-[[[2-(acetylamino)-6-methyl-3-pyridinyl]methyl]formylamino]-1-[2-(acetyloxy)ethyl]-1-propen-1-yl]thio]methyl ester (CA INDEX NAME)




RN 866721-27-9 CAPLUS
 CN Ethanethioic acid, S-[1-[2-(acetyloxy)ethyl]-2-[[2-(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propen-1-yl] ester (CA INDEX NAME)




RN 866721-28-0 CAPLUS
 CN Benzenecarbothioic acid, S-[1-[2-(acetyloxy)ethyl]-2-[[2-(2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-propen-1-yl] ester (CA INDEX NAME)



RN 866721-29-1 CAPLUS
 CN Benzenecarbothioic acid, S-[2-[[2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-[2-(benzoyloxy)ethyl]-1-propen-1-yl] ester
 (CA INDEX NAME)



RN 866721-30-4 CAPLUS
 CN Benzenecarbothioic acid, S-[2-[[2-amino-6-methyl-3-pyridinyl)methyl]formylamino]-1-[2-[(diethoxyphosphinyl)oxy]ethyl]-1-propen-1-yl] ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stnguide
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
17.93	209.69

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-2.55	-2.55

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:45:10 ON 17 FEB 2010
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 15, 2010 (20100215/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.77

210.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.55

STN INTERNATIONAL LOGOFF AT 11:51:38 ON 17 FEB 2010